.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE34990

« Back to Dashboard

Claims for Patent: RE34990

Title: Oral therapeutic system having systemic action
Abstract:The invention relates to a therapeutic system for peroral administration and having systemic action, which system is in the form of a coated and/or laminated mono-compartment system for administering carbamazepine. The therapeutic system comprises (a) a wall made of a material which is permeable to water and impermeable to the components of the drug-containing core, (b) a core containing finely particulate carbamazepine as drug and, as auxiliaries, a protective colloid that inhibits the crystal growth of carbamazepine in the presence of water, a swellable hydrophilic polymer and, optionally, a water-soluble compound for inducing osmosis and/or further pharmaceutically acceptable excipients, and (c) a passageway through the wall (a) for delivering the core components to the environmental body fluid. The therapeutic system can be used as an anticonvulsive for the treatment of convulsive states, especially epileptic states.
Inventor(s): Khanna; Satish C. (Bottmingen, CH), Ruttimann; Theresa (Basel, CH)
Assignee: Ciba-Geigy Corporation (Ardsley, NY)
Application Number:08/133,814
Patent Claims: 1. An oral therapeutic system for administering carbamazepine comprising

(a) a wall made of acylated cellulose which is permeable to water but impermeable to the components of the drug containing core and to the ions present in gastric or intestinal juices;

(b) a core containing finely particulate carbamazepine as a drug, hydroxypropylmethyl cellulose as protective colloid, a swellable hydrophilic polymer selected from the group consisting of poly-N-vinyl-2-pyrrolidone, polyvinyl alcohol, alkylene oxide homopolymers, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, the copolymer of vinylpyrrolidone and vinyl acetate, the mixture of the copolymer of vinylpyrrolidone and vinyl acetate and the homopolymer of ethylene oxide and, a water soluble compound for inducing osmosis; and

(c) a passageway through the wall (a) for delivering the components present in the core to the environmental gastric or intestinal juices.

2. An oral therapeutic system according to claim 1, comprising

(a) a wall made of acylated cellulose which is permeable to water but impermeable to the components of the drug-containing core and to the ions present gastric or intestinal juices,

(b) a core containing finely particulate carbamazepine as drug, hydroxymethyl cellulose as protective colloid, a 1:1 mixture % by weight of a copolymer of vinylpyrrolidone and vinyl acetate and a homopolymer of ethylene oxide as swellable hydrophilic polymer, and and

(c) passageway through the wall (a) for delivering the components present in the core to the environmental aqueous body fluid.

3. An oral therapeutic system according to claim 1, comprising

(a) a wall made of cellulose acetate which is permeable to water but impermeable to the components of the drug-containing core and to the ions present in gastric or intestinal juices,

(b) a core containing carbamazepine as drug, hydroxypropyl methylcellulose as protective colloid, a 1:1 mixture % by weight of a copolymer of vinylpyrrolidone and vinyl acetate having a molecular weight of 60.000.+-.15,000 and having a monomer ratio of 60:40% by weight and a homopolymer of ethylene oxide having a degree of polymerisation of 2000 to 100,000 as swellable hydrophilic polymer, and

(c) a passageway through the wall (a) for delivering the components present in the core to the environmental gastric or intestinal juices.

4. An oral therapeutic system according to claim 1, which contains anhydrous microcrystals of carbamazepine.

5. An oral therapeutic system according to claim 1, which contains anhydrous microcrystals of carbamazepine having a size of up to 20 .mu.m, and hydroxypropyl methylcellulose as protective colloid.

6. The therapeutic system of claim 2 further comprising a compound for inducing osmosis selected from sodium chloride, potassium chloride, glucose, and mannitol.

7. The therapeutic system of claim 3 further comprising a compound for inducing osmosis selected from sodium chloride, potassium chloride, glucose and mannitol. .Iadd.

8. An oral therapeutic system for administrating carbamazepine comprising

(a) a wall made of acylated cellulose which is permeable to water but impermeable to the components of the drug containing core and to the ions present in gastric or intestinal juices;

(b) a core containing finely particulate carbamazepine as a drug, hydroxypropylmethyl cellulose as protective colloid, a swellable hydrophilic polymer selected from the group consisting of poly-N-vinyl-2-pyrrolidone, polyvinyl alcohol, alkylene oxide homopolymers, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, the copolymer of vinyl pyrrolidone and vinyl acetate, the mixture of the copolymer of vinylpyrrolidone and vinyl acetate and the homopolymer of ethylene oxide and, a water soluble compound for inducing osmosis; and

(c) a passageway through the wall (a) for delivering the components present in the core to the environmental gastric or intestinal juices. .Iaddend. .Iadd.9. The oral therapeutic system of claim 8 wherein 2 swellable hydrophilic polymers are present. .Iaddend. .Iadd.10. The oral therapeutic system of claim 8 wherein said carbamazepine is present as anhydrous microcrystals. .Iaddend. .Iadd.11. The oral therapeutic system of claim 10 wherein carbamazepine microcrystals have a size of up to 20um, and said protective colloid is hydroxypropyl methylcellulose. .Iaddend. .Iadd.12. The oral therapeutic system of claim 8 further comprising a compound for inducing osmosis selected from sodium chloride, potassium chloride, and carbohydrates. .Iaddend. .Iadd.13. The oral therapeutic system of claim 11 further comprising a compound for inducing osmosis selected from sodium chloride, potassium chloride, and carbohydrates. .Iaddend. .Iadd.14. The oral therapeutic system of claim 8 wherein said core comprises anhydrous carbamazepine, hydroxypropyl methylcellulose, hydroxyethylcellulose, and mannitol. .Iaddend. .Iadd.15. The oral therapeutic system of claim 8 wherein said wall comprises cellulose acetate, hydroxypropyl methylcellulose, and polyethylene glycol 8000. .Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc